CureVac N.V. Stock News

CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current revenues. CVAC boasts over 25 years of research and nearly 1,000 mRNA patents, highlighting its intellectual property strength.

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pen...

CureVac / NL0015436031

CureVac / NL0015436031

GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine technology. The deal will also see GSK collect a 1% royalty on United States sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from the start of 2025.

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.

Vor der angekündigten Übernahme von Curevac NL0015436031 durch den deutschen Konkurrenten Biontech US09075V1026 haben die beiden Unternehmen aus Tübingen und Mainz ihren Patentstreit um Corona-Impfstoff-Patente beigelegt.

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.